DelveInsight launched a new report on Trastuzumab Biosimilar Insights 2020.
DelveInsight’s, “Trastuzumab Biosimilar Insight, 2020,” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in the Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used by itself or together with other chemotherapy medications. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.
Trastuzumab Marketed drugs:
- Kanjinti by Amgen
- Herzuma by Celltrion
Trastuzumab Emerging drugs:
- EG12014 by EirGenix
- HD201 by Prestige BioPharma
Pipeline Development Activities
The report covers detailed information of collaborations, acquisition, and merger, licensing along a thorough therapeutic assessment of emerging Trastuzumab biosimilar drugs.
Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/trastuzumab-biosimilars-insight
Table of contents:
1. Key Insights
2. Trastuzumab Biosimilars: Snapshot
3. Executive Summary
4. Regulatory Outlook For Biosimilars
5. Trastuzumab (Reference Product: Herceptin)
6. Research and Development
7. Herceptin Biosimilar: Emerging Opportunities
8. Trastuzumab: Biosimilars Assessment
9. Trastuzumab Biosimilars Profiles: By Company
10. Trastuzumab Biosimilars: Comparative Landscape: By Company
11. Trastuzumab Biosimilars: Competitive Landscape
12. Market Drivers
13. Market Barriers
14. SWOT Analysis
17. DelveInsight Capabilities
19. About DelveInsight
Download our full report: https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States